• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【分子编号】11006

【品名】2-Amino-6-(bromomethyl)-4-pteridinylamine; 6-(Bromomethyl)-2,4-pteridinediamine

【CA登记号】52853-40-4

【 分 子 式 】C7H7BrN6

【 分 子 量 】255.07702

【元素组成】C 32.96% H 2.77% Br 31.33% N 32.95%

与该中间体有关的原料药合成路线共 6 条

合成路线1

该中间体在本合成路线中的序号:(I)

A new synthesis for edatrexate has been described: The reaction of 2,4-diamino-6-(bromomethyl)pteridine (I) with tributylphosphine (II) in DMSO gives the corresponding phosphonium salt (III), which is condensed wtih 4-propionylbenzoic acid methyl ester (IV) by means of NaH in DMSO, affording 4-[1-(2,4-diaminopteridin-6-yl)-1-ethylvinyl]benzoic acid methyl ester (V). The hydrogenation of (V) with H2 and PtO2 in acetic acid gives 4-[1-(2,4-diamino-6,7-dihydropteridin-6-ylmethyl)propyl]benzoic acid methyl ester (VI), which, without isolation, is dehydrogenated with H2O2 in the same solvent yielding 4-[1-(2,4-diaminopteridin-6-ylmethyl)propyl]benzoic acid methyl ester (VII). The hydrolysis of (VII) with NaOH in DMSO - water affords the corresponding free acid (VIII), which is condensed with L-glutamic acid diethyl ester (IX) by means of isobutoxycarbonylchloride and triethylamine in DMF, giving edatrexate diethyl ester (X). Finally, this compound is hydrolyzed with NaOH in methanol.

1 Johnson, C.A.; Sirotnak, F.M.; Piper, J.R.; Otter, G.M.; Synthesis and antifolate evaluation of 10-ethyl-5-methyl-5,10-dideazaaminopterin and an alternative synthesis of 10-ethyl-10-deazaaminopterin (edatrexate). J Med Chem 1992, 35, 16, 3002.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 11006 2-Amino-6-(bromomethyl)-4-pteridinylamine; 6-(Bromomethyl)-2,4-pteridinediamine 52853-40-4 C7H7BrN6 详情 详情
(III) 11007 Tributyl[(2,4-diamino-6-pteridinyl)methyl]phosphonium bromide C19H34BrN6P 详情 详情
(IV) 11008 methyl 4-propionylbenzoate C11H12O3 详情 详情
(V) 11009 methyl 4-[(E)-2-(2,4-diamino-6-pteridinyl)-1-ethylethenyl]benzoate C18H18N6O2 详情 详情
(VI) 11010 methyl 4-[1-[(2,4-diamino-5,6,7,8-tetrahydro-6-pteridinyl)methyl]propyl]benzoate C18H24N6O2 详情 详情
(VII) 11011 methyl 4-[1-[(2,4-diamino-6-pteridinyl)methyl]propyl]benzoate C18H20N6O2 详情 详情
(VIII) 11012 4-[1-[(2,4-Diamino-6-pteridinyl)methyl]propyl]benzoic acid C17H18N6O2 详情 详情
(IX) 11013 diethyl (2S)-2-aminopentanedioate C9H17NO4 详情 详情
(X) 11014 diethyl (2S)-2-[(4-[1-[(2,4-diamino-6-pteridinyl)methyl]propyl]benzoyl)amino]pentanedioate C26H33N7O5 详情 详情

合成路线2

该中间体在本合成路线中的序号:(VI)

Carboxilic acid (I) is converted to the correspondig acid chloride (II) and and amidated with dimethyl homoglutamate (III) to give the amide (IV). The benzyloxycarbonyl grouo of the amide (IV) is removed with H2 over Pd/C to give the amide (V), which is effectively alkylated with 6-(bromomethyl)-2,4-diaminopteridine (VI) to produce compound (VII). Finally, compound (VII) is hydrolyzed with 1N NaoH to yield MX-68.

1 Maruyama, N.; et al.; Antirheumatic agents. Novel methotrexate derivatives which are resistant to polyglutamation. 213th ACS Natl Meet (April 13-17, San Francisco) 1997, Abst MEDI 090.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 19819 4-[(benzyloxy)carbonyl]-3,4-dihydro-2H-1,4-benzothiazine-7-carboxylic acid C17H15NO4S 详情 详情
(II) 19820 benzyl 7-(chlorocarbonyl)-2,3-dihydro-4H-1,4-benzothiazine-4-carboxylate C17H14ClNO3S 详情 详情
(III) 19821 dimethyl (2S)-2-aminohexanedioate C8H15NO4 详情 详情
(IV) 19822 dimethyl (2S)-2-[([4-[(benzyloxy)carbonyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl)amino]hexanedioate C25H28N2O7S 详情 详情
(V) 19823 dimethyl (2S)-2-[(3,4-dihydro-2H-1,4-benzothiazin-7-ylcarbonyl)amino]hexanedioate C17H22N2O5S 详情 详情
(VI) 11006 2-Amino-6-(bromomethyl)-4-pteridinylamine; 6-(Bromomethyl)-2,4-pteridinediamine 52853-40-4 C7H7BrN6 详情 详情
(VII) 19825 dimethyl (2S)-2-[([4-[(2,4-diamino-6-pteridinyl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl)amino]hexanedioate C24H28N8O5S 详情 详情

合成路线3

该中间体在本合成路线中的序号:(IX)

As shown in Scheme 22540502a, initially, starting material (I) is converted to benzothiazol (II) by treatment of sodium thiocyanate in the presence of bromine. Alkali hydrolysis of compound (II) gives thiol (III), which is immediatly submitted to S-alkylation with 1-bromo-2-chloroethane, followed by acid esterification, which gives thioether (IV). After protection of the amino group of compound (IV) with tosyl chloride, treatment of NaOH affords benzothiazine ester (V), and next hydrolysis produces the key intermediate (VI). Subsequently, compound (VI) is converted to the corresponding acid chloride and amidated with dimethyl homoglutamate to give the amide (VII). The tosyl group of the amide (VII) is removed with HBr-AcOH to give the amine (VIII), which is effectively alkilated with 6-(bromomethyl)-,4-diaminopteridine (IX) to produce (X). Finally, compound (X) is hydrolyzed with 1N NaOH to yield MX-68.

1 Matsuoka, H.; et al.; Antirheumatic agents: Novel methotrexate derivatives bearing a benzoxazine or benzothiazine moiety. J Med Chem 1997, 40, 1, 105.
2 Mihara, M.; Matsuoka, H.; The synthesis and biological evaluation of new methotrexate derivatives in rheumatoid arthritis. Drugs Fut 1998, 23, 9, 1015.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 20004 p-aminobenzoic acid; 4-aminobenzoic acid 150-13-0 C7H7NO2 详情 详情
(II) 25039 2-amino-1,3-benzothiazole-6-carboxylic acid C8H6N2O2S 详情 详情
(III) 25040 4-amino-3-sulfanylbenzoic acid hydrochloride C7H8ClNO2S 详情 详情
(IV) 25041 methyl 4-amino-3-[(2-chloroethyl)sulfanyl]benzoate hydrochloride C10H13Cl2NO2S 详情 详情
(V) 25042 methyl 4-[(4-methylphenyl)sulfonyl]-3,4-dihydro-2H-1,4-benzothiazine-7-carboxylate C17H17NO4S2 详情 详情
(VI) 25043 4-[(4-methylphenyl)sulfonyl]-3,4-dihydro-2H-1,4-benzothiazine-7-carboxylic acid C16H15NO4S2 详情 详情
(VII) 25044 dimethyl 2-[([4-[(4-methylphenyl)sulfonyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl)amino]hexanedioate C24H28N2O7S2 详情 详情
(VIII) 19823 dimethyl (2S)-2-[(3,4-dihydro-2H-1,4-benzothiazin-7-ylcarbonyl)amino]hexanedioate C17H22N2O5S 详情 详情
(IX) 11006 2-Amino-6-(bromomethyl)-4-pteridinylamine; 6-(Bromomethyl)-2,4-pteridinediamine 52853-40-4 C7H7BrN6 详情 详情
(X) 19825 dimethyl (2S)-2-[([4-[(2,4-diamino-6-pteridinyl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl)amino]hexanedioate C24H28N8O5S 详情 详情

合成路线4

该中间体在本合成路线中的序号:(I)

The synthetic scheme of tritiated MX-68 ia also presented in Scheme 22540503a. Treatment of compound (I) with triphenylphosphine, followed by Wittig reaction with 4-ethylbenzoic aldehyde (II) yields an olefin (III). To improve the solubility of (III) in routine organic solvents, the amino group of compound (III) is acylated with anhydride (IV) to give a lipophilic olefin (V). The olefin moiety is next oxidized by treatment of ozone to give an aldehyde (VI). Reduction of compound (VI) with NaBT4 is performed in isopropanol to give the corresponding tritiated alcohol (VII). The alohol (VII) is deacylated to yield acyl-free pteridine (VIII). The conversion of compound (VIII) to HBr salt, followed by bromination of alcohol with dibromotriphenylphosphorane, amination with compound (IX) and alkali hydrolysis produces [9-3H]-MX-68.

1 Matsuoka, H.; et al.; Synthesis of tritiated N-[4-(2, 4-diaminopteridine-6-methyl)-3,4-dihydro-2H-1, 4-benzothiazine-7-carbonyl]-L-homo glutamic acid (MX-68). J Label Compd Radiopharm 1997, 39, 5, 363.
2 Mihara, M.; Matsuoka, H.; The synthesis and biological evaluation of new methotrexate derivatives in rheumatoid arthritis. Drugs Fut 1998, 23, 9, 1015.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 11006 2-Amino-6-(bromomethyl)-4-pteridinylamine; 6-(Bromomethyl)-2,4-pteridinediamine 52853-40-4 C7H7BrN6 详情 详情
(II) 25045 4-ethylbenzaldehyde 4748-78-1 C9H10O 详情 详情
(III) 25046 6-(4-ethylstyryl)-2,4-pteridinediamine C16H16N6 详情 详情
(IV) 25047 butyric anhydride 106-31-0 C8H14O3 详情 详情
(V) 25048 N-[2-(butyrylamino)-6-(4-ethylstyryl)-4-pteridinyl]butanamide C24H28N6O2 详情 详情
(VI) 25049 N-[2-(butyrylamino)-6-formyl-4-pteridinyl]butanamide C15H18N6O3 详情 详情
(VII) 25050 N-[2-(butyrylamino)-6-(hydroxymethyl)-4-pteridinyl]butanamide C15H20N6O3 详情 详情
(VIII) 20068 (2,4-diamino-6-pteridinyl)methanol 945-24-4 C7H8N6O 详情 详情
(IX) 19823 dimethyl (2S)-2-[(3,4-dihydro-2H-1,4-benzothiazin-7-ylcarbonyl)amino]hexanedioate C17H22N2O5S 详情 详情

合成路线5

该中间体在本合成路线中的序号:(VI)

The first synthetic method started from 2,4-diamino-6-(hydroxymethyl)-pteridine (V). Conversion of (V) into the corresponding bromide (VI) was achieved by treatment with triphenylphosphine dibromide. Ylide (VII) was then prepared by reaction of bromide (VI) with triphenylphosphine, followed by deprotonation using potassium tert-butoxide. Wittig reaction between ylide (VII) and aldehyde (IV) produced the olefin (VIII), assumed to be a mixture of geometric isomers. Catalytic hydrogenation of olefin (VIII), followed by reoxidation of the pteridine ring with H2O2, yielded (IX). Finally, hydrolysis of (IX) with NaOH gave rise to the title compound.

1 Rosowsky, A.; Vaidya, C.M.; Wright, J.E.; Forsch, R.A.; Bader, H.; Analogues of the potent nonpolyglutamatable antifolate Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: Synthesis and in vitro antitumor activity. J Med Chem 2000, 43, 8, 1620.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(VIIIa) 42878 methyl (2S)-2-([4-[(E)-2-(2,4-diamino-6-pteridinyl)ethenyl]benzoyl]amino)-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)pentanoate C29H26N8O5 详情 详情
(VIIIb) 42879 methyl (2S)-2-([4-[(Z)-2-(2,4-diamino-6-pteridinyl)ethenyl]benzoyl]amino)-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)pentanoate C29H26N8O5 详情 详情
(IV) 42876 methyl (2S)-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-[(4-formylbenzoyl)amino]pentanoate C22H20N2O6 详情 详情
(V) 20068 (2,4-diamino-6-pteridinyl)methanol 945-24-4 C7H8N6O 详情 详情
(VI) 11006 2-Amino-6-(bromomethyl)-4-pteridinylamine; 6-(Bromomethyl)-2,4-pteridinediamine 52853-40-4 C7H7BrN6 详情 详情
(VII) 42877 triphenyl-N-[2-[(triphenylphosphoranylidene)amino]-6-[(triphenylphosphoranylidene)methyl]-4-pteridinyl]phosphine imide; 2,4-bis[(triphenylphosphoranylidene)amino]-6-[(triphenylphosphoranylidene)methyl]pteridine C61H47N6P3 详情 详情
(IX) 42880 methyl (2S)-2-([4-[2-(2,4-diamino-6-pteridinyl)ethyl]benzoyl]amino)-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)pentanoate C29H28N8O5 详情 详情

合成路线6

该中间体在本合成路线中的序号:(III)

 

1 DeGraw JI, Colwell WT, Piper JR, et al. 1993. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. Journal of Medicinal Chemistry, 36(15): 2228~2231.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 67360 methyl 4-(2-methoxy-2-oxoethyl)benzoate 52787-14-1 C11H12O4 详情 详情
(II) 67361 methyl 4-(1-methoxy-1-oxopent-4-yn-2-yl)benzoate   C14H14O4 详情 详情
(III) 11006 2-Amino-6-(bromomethyl)-4-pteridinylamine; 6-(Bromomethyl)-2,4-pteridinediamine 52853-40-4 C7H7BrN6 详情 详情
(IV) 67362 methyl 4-(2-((2,4-diaminopteridin-6-yl)methyl)-1-methoxy-1-oxopent-4-yn-2-yl)benzoate   C21H20N6O4 详情 详情
(V) 67363 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid 146464-93-9 C18H16N6O2 详情 详情
(VI) 67364 (S)-diethyl 2-aminopentanedioate   C9H17NO4 详情 详情
(VII) 67365 (2S)-diethyl 2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioate   C27H31N7O5 详情 详情
Extended Information